TRU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, TransUnion (TRU) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the company has shown strong financial performance in the latest quarter, the lack of clear trading signals, neutral insider and hedge fund activity, and mixed analyst sentiment suggest that waiting for a more favorable entry point might be prudent. The pre-market price of $70.41 is below most analyst price targets, which could indicate upside potential, but current technical indicators and sentiment do not strongly support an immediate buy.
The MACD is positively expanding, and the RSI is neutral at 57.056, indicating no overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot level of 69.15, with resistance at 72.155 and support at 66.146. Overall, the technical indicators suggest a neutral trend.
Strong Q4 financial performance with revenue up 12.97% YoY, net income up 52.87% YoY, and EPS up 57.58% YoY.
Analysts maintain a generally bullish outlook, with multiple buy ratings and price targets significantly above the current price.
Strategic AI initiatives and strong performance in U.S. markets, particularly in emerging verticals.
Mixed analyst sentiment, with several firms lowering price targets due to concerns about slower economic recovery in India and tighter international credit conditions.
Declining gross margin, down 0.66% YoY.
Neutral insider and hedge fund activity, with no significant trading trends.
Rising competition in AI-driven credit scoring from companies like Upstart.
In Q4 2025, TransUnion reported strong financial results: Revenue increased by 12.97% YoY to $1.171 billion, net income rose by 52.87% YoY to $101.2 million, and EPS grew by 57.58% YoY to $0.52. However, gross margin declined slightly to 46.75%, down 0.66% YoY.
Analysts are mixed but lean positive. Morgan Stanley and Clear Street maintain bullish views with price targets of $100 and $94, respectively. BofA upgraded the stock to Neutral with a price target of $83. Several analysts lowered price targets due to mixed guidance and macroeconomic concerns, but most retain Buy or Overweight ratings.
